Principal Financial Group Inc Esperion Therapeutics, Inc. Transaction History

Principal Financial Group Inc

  • $184 Billion
  • Q3 2025

A detailed history of Principal Financial Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 190,056 shares of ESPR stock, worth $551,162. This represents 0.0% of its overall portfolio holdings.

Number of Shares
190,056
Previous 393,290 51.68%
Holding current value
$551,162
Previous $385,000 30.65%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 04, 2025
SELL
$0.98 - $2.84 $199,169 - $577,184
-203,234 Reduced 51.68%
190,056 $503,000
Q2 2025

Aug 08, 2025
BUY
$0.73 - $1.41 $277,424 - $535,847
380,034 Added 2866.88%
393,290 $385,000
Q1 2025

Apr 28, 2025
BUY
$1.44 - $2.34 $1,666 - $2,707
1,157 Added 9.56%
13,256 $19,000
Q4 2024

Jan 31, 2025
BUY
$1.61 - $3.83 $19,479 - $46,339
12,099 New
12,099 $26,000
Q3 2024

Oct 31, 2024
SELL
$1.61 - $2.73 $8,188 - $13,884
-5,086 Reduced 24.89%
15,344 $25,000
Q2 2024

Jul 29, 2024
SELL
$1.84 - $3.24 $16,046 - $28,256
-8,721 Reduced 29.92%
20,430 $45,000
Q1 2024

Apr 29, 2024
SELL
$2.02 - $3.02 $9,053 - $13,535
-4,482 Reduced 13.33%
29,151 $78,000
Q4 2023

Feb 07, 2024
SELL
$0.73 - $3.08 $586 - $2,473
-803 Reduced 2.33%
33,633 $100,000
Q3 2023

Nov 02, 2023
BUY
$0.96 - $1.79 $2,782 - $5,187
2,898 Added 9.19%
34,436 $33,000
Q2 2023

Aug 07, 2023
BUY
$1.2 - $1.76 $14,697 - $21,556
12,248 Added 63.49%
31,538 $43,000
Q1 2023

May 09, 2023
SELL
$1.46 - $7.3 $2,114 - $10,570
-1,448 Reduced 6.98%
19,290 $30,000
Q4 2022

Feb 09, 2023
BUY
$5.09 - $8.5 $19,759 - $32,997
3,882 Added 23.03%
20,738 $129,000
Q3 2022

Nov 09, 2022
SELL
$5.45 - $8.13 $773 - $1,154
-142 Reduced 0.84%
16,856 $113,000
Q2 2022

Aug 10, 2022
BUY
$4.77 - $6.67 $31,057 - $43,428
6,511 Added 62.09%
16,998 $108,000
Q1 2022

May 09, 2022
BUY
$3.34 - $5.56 $35,026 - $58,307
10,487 New
10,487 $49,000
Q4 2020

Feb 08, 2021
SELL
$24.2 - $35.76 $134,527 - $198,789
-5,559 Closed
0 $0
Q3 2020

Nov 06, 2020
SELL
$31.18 - $52.71 $141,900 - $239,883
-4,551 Reduced 45.01%
5,559 $206,000
Q2 2020

Aug 05, 2020
BUY
$30.04 - $51.31 $303,704 - $518,744
10,110 New
10,110 $518,000
Q1 2020

May 12, 2020
SELL
$27.44 - $73.84 $108,827 - $292,849
-3,966 Closed
0 $0
Q4 2019

Feb 05, 2020
SELL
$35.4 - $59.82 $23,080 - $39,002
-652 Reduced 14.12%
3,966 $236,000
Q1 2018

May 14, 2018
BUY
$65.94 - $80.76 $29,607 - $36,261
449 Added 10.77%
4,618 $334,000
Q4 2017

Feb 13, 2018
BUY
$43.47 - $67.43 $181,226 - $281,115
4,169
4,169 $274,000

Others Institutions Holding ESPR

# of Institutions
215
Shares Held
114M
Call Options Held
643K
Put Options Held
769K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $193M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email